Lipoprotein(a) and its impact on cardiovascular disease – the Polish perspective: Design, and first results of the Zabrze-Lipoprotein(a) Registry

Archives of Medical Science, Journal Year: 2024, Volume and Issue: 20(4), P. 1069 - 1076

Published: May 6, 2024

Introduction Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Increased Lp(a) concentration > 30 mg/dl (75 nmol/l) and especially >50 (125 may cause faster atherosclerosis, being important underdiagnosed residual factor. Thus, there a need to characterize further the clinical phenotypes in patients at ASCVD with high levels now during follow-up, while also looking possible impact of geographical differences. Material methods The Zabrze Registry (Zabrze-Lip(a)R) was founded on basis data from 2,001 consecutive very treated tertiary hospital. registry will be followed least 5 years possibility extending this period as open label study. All-cause cause-specific mortality, hospitalizations, events, such myocardial infarction (MI) stroke, assessed. Results mean age 66.4 (females 37.1%). median entire population 6.6 (16.5 (mean: 14.3 ±19.4 mg/dl). 540 (27%) had elevated above nmol/l); they were significantly older (68.8 vs. 66.3 years; p = 0.04), lower hemoglobin hematocrit, higher platelet count NT-proBNP C-reactive protein. prevalence concentrations chronic coronary syndrome (CCS) (52.2% (282/540) 41.5% (607/1461); < 0.001), undergoing PCI hospitalization (23.9 19%; 0.01), previous MI (20.6% 14.9%; 0.0022). In multivariable analysis, predictors only Hb values (OR 0.925; 95% CI: 0.874–0.978; 0.006) (1.002; 95%CI: 1.000–1.003; 0.02). Conclusions Poland, largest representative Central Eastern European countries, 27% established experience additional related level, every second patient having CCS. Interestingly, two factors levels: count. However, relevance these results needs confirmation.

Language: Английский

The role of lipoprotein(a) in atrial fibrillation: a systematic review

Polskie Archiwum Medycyny Wewnętrznej, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

What's new?Lipoprotein(a) [Lp(a)], a variant of low-density lipoprotein, is an established causal risk factor for atherosclerotic cardiovascular disease and aortic stenosis.While evidence supporting its role in other conditions limited, some studies reported it played pathophysiological atrial fibrillation (AF).This research systematically reviews current knowledge on the Lp(a) AF, providing study-by-study analysis overall conclusions.To best our knowledge, this first systematic review AF that includes various study types.We found little to support association between levels incidence.However, genetic show relationship high AF.Among patients, those who experienced thromboembolic events had higher concentrations than did not.

Language: Английский

The need for national and international registries of patients with elevated lipoprotein(a)

Current Opinion in Lipidology, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

Purpose of review Elevated lipoprotein(a) [Lp(a)] is a genetically determined independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Current guidelines recommend universal testing Lp(a) once in an individual's lifetime, with management intensification those elevated levels. However, there paucity real-world data about how patients are managed and their associated risk. The purpose this to discuss recent progress the establishment registries Lp(a). Recent findings Multiple that include have been established various countries. These studies will provide snapshot global burden condition current patterns treatment patient population. Summary common but underdiagnosed ASCVD. National international needed expand our understanding improve condition.

Language: Английский